Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2007

View Archived Issues

Recent patents cover new therapeutic agents for cancer

Novel treatments for musculoskeletal and connective tissue disorders claimed in recent patents

Recent Schering and Epix patents disclose novel MRI agents

Novel treatment options for gastrointestinal disorders reported in recent patents

Phase IIa study of oleoyl-estrone for obesity completes enrollment

Identification of active sites of Polo-like kinases useful for developing new cancer therapies

Access to acquire Somanta

GCN2 critical for regulating fat metabolism during essential amino acid deprivation

Apollo Life Sciences reduces inflammation with oral TNF blocker

Dyax and Genzyme end DX-88 joint venture

IAVI applauds creation of Canadian HIV Vaccine Initiative

Avax collaborates with CTCA on O-Vax vaccine

AlphaRx's nanoparticle drug delivery system shows potential in tuberculosis

GPC Biotech launches satraplatin expanded access program

TransTech licenses Novo Nordisk's GKA program

Hybrigenics focuses research on USP inhibitors for cancer

DiaKine licenses cytokine modulators from U. of Virginia

Orphan drug status awarded to rhPDGF-BB for osteonecrosis of the jaw

Pharmacyclics receives refusal to file letter for Xcytrin

Avastin plus chemotherapy improves PFS in advanced NSCLC patients

Indena patents novel compounds for treating skeletal muscle spasms

Fosrenol launched in U.K.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...